ViRexx Medical Corp.
TSX : VIR

ViRexx Medical Corp.

September 30, 2005 11:58 ET

Dr. Lorne Tyrrell of ViRexx Wins Prestigious EnCana Principal Award

EDMONTON, ALBERTA--(CCNMatthews - Sept. 30, 2005) - ViRexx Medical Corp. (TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors, announced that Dr. Lorne Tyrrell, a world renowned virologist and Chief Scientific Officer and co-founder of ViRexx, has been awarded the top prize from the Ernest C. Manning Awards Foundation for his breakthrough work in the development of the first effective oral medication for hepatitis B. The prestigious prize, known as the EnCana Principal Award, is presented to recognize and reward Canadian innovators and carries with it a $100,000 prize.

Dr. Tyrrell's research at the University of Alberta led to the development of the patented anti-viral drug, lamivudine, for the treatment of chronic hepatitis B (HBV) infection. The drug, marketed by GlaxoSmithKline under the name Epivir®, dramatically suppresses the virus's ability to reproduce in the body. Treatment with lamivudine has slowed or prevented the life-shortening consequences of this devastating disease, including cirrhosis and liver cancer. It also provides the opportunity for HBV infected patients with advanced liver disease to receive and benefit from liver transplants. Approximately 400 million people are chronic HBV carriers and chronic HBV infection leads to more than one million premature deaths annually.

Marc Canton, President and Chief Operating Officer of ViRexx, commented, "This award highlights what has been known in the scientific and medical fields for many years - that Dr. Tyrrell is one of the most innovative and respected people in the field of virology. We are very fortunate to have one of the world's elite scientists as our Chief Scientific Officer guiding the commercialization strategy for our program to create vaccines for the treatment of hepatitis B and C."

Dr. Tyrrell is a Professor of Medical Microbiology and Immunology at the University of Alberta and Director of the Centre of Excellence for Viral Hepatitis Research. His numerous awards include the Order of Canada, the Alberta Order of Excellence, the Prix Galien Canada Medal for Research and the Canadian Medical Association's FNG Starr Award.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C and solid tumors.

ViRexx's lead product, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of a Phase III clinical trial being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.

The TSX has not approved or disapproved of the information contained herein.

Contact Information

  • ViRexx Medical Corp.
    Rob Salmon
    Chief Financial Officer
    (780) 989-6708
    (780) 436-0068 (FAX)
    Email: rsalmon@virexx.com
    or
    The Equicom Group Inc.
    Ross Marshall
    Investor Relations
    (800) 385 5451 ext. 238
    (416) 815-0080 (FAX)
    Email: rmarshall@equicomgroup.com
    or
    Lippert/Heilshorn & Associates Inc.
    Kim Golodetz
    Investor Relations
    (212) 838-3777
    (212) 838-4568 (FAX)
    Email: kgolodetz@lhai.com